FDA's risk communication plan coming soon
This article was originally published in The Tan Sheet
Executive Summary
FDA could release its strategic plan to ensure it accurately communicates to consumers the risks and benefits of medical products in as early as one month, according to Janet Woodcock, director of the Center for Drug Evaluation and Research. The plan will include a list of 14 actions FDA will take in the next year to improve its risk communication strategies. It will also list around 60 actions FDA hopes to take in the next few years, Woodcock said Sept. 21 at the Food and Drug Law Institute conference in Washington
You may also be interested in...
Lilly Can Rest Easy As Tirzepatide Scores Phase III Sleep Apnea Win
Topline results from two studies in obstructive sleep apnea among obese adults showed efficacy crossing the 50% threshold that physicians have called clinically meaningful.
China’s Public Payer Wants To Define Innovative Drugs As Those With ‘Novel Benefits’
China’s public payer perceives innovative drugs in a different way from that of the country’s top drug regulator, a former senior healthcare security official with knowledge of the matter reveals. The posture has unnerved pharma companies, which have been hit by sharp price discounts.
Change Is Constant For Pneumococcal Vaccines: US CDC Prepares For Merck’s V116
As Merck’s 21-valent vaccine approaches its 17 June user fee goal, the US CDC’s vaccine committee is looking at new adult age-based recommendations and bracing for a full pipeline led by GSK’s 24-valent candidate.